Finding new treatment targets in metastatic stomach cancer
Identification of Novel Therapeutic Targets in Gastric Cancer With Lymph Node or Distant Metastasis: An Explorative Study
This pilot project will try to find molecular targets in adults with metastatic stomach cancer to help guide future treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT07551440 on ClinicalTrials.gov |
What this trial studies
This is a single-center pilot observational project at the Prince of Wales Hospital that will screen adults diagnosed with gastric adenocarcinoma that has spread to lymph nodes or distant sites. Enrolled patients who are scheduled for neoadjuvant or palliative chemotherapy, targeted therapy, or immunotherapy will have tumor samples and clinical data collected. The samples will undergo molecular profiling to identify potential therapeutic targets. The goal is to generate candidate targets that can be tested in later clinical trials.
Who should consider this trial
Good fit: Adults 18–80 years old with gastric adenocarcinoma and lymph node or distant metastases, WHO performance status ≤2, who will receive neoadjuvant or palliative systemic therapy and can consent are ideal candidates.
Not a fit: People who will not receive neoadjuvant or palliative systemic therapy, who are pregnant or breastfeeding, or who have irreversible coagulation disorders are unlikely to participate or benefit from this project.
Why it matters
Potential benefit: If successful, the study could reveal new molecular targets that lead to more effective, personalized treatments for metastatic stomach cancer.
How similar studies have performed: Previous molecular profiling in gastric cancer has identified actionable markers such as HER2 amplification, MSI status, and PD-L1 expression, supporting this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients age \>= 18, \<= 80 years old 2. Performance status (WHO) \<=2 3. Gastric adenocarcinoma with lymph node metastasis or distant metastasis such as liver metastases, lung metastases, bone metastases, peritoneum metastases 4. Patients with isolated ovarian metastasis could be included 5. Patients who will be undergoing neoadjuvant chemotherapy/ target therapy/ immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy 6. Ability to give written consent before the commencement of treatment Exclusion Criteria: 1. Patient who will not be undergoing neoadjuvant chemotherapy/ target therapy/ immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy 2. Pregnancy or breastfeeding 3. Patients with irreversible coagulation disorders
Where this trial is running
Hong Kong
- The Chinese University of Hong Kong — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Study coordinator: Shannon Melissa Chan, PhD
- Email: shannonchan@surgery.cuhk.edu.hk
- Phone: 35052627
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.